SCHEMBL3754134

SCHEMBL3754134

O=c1c(OCP(=O)(O)O)c(-c2ccc(O)c(O)c2)oc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.62
HSD17B10 Q99714 5/20 0.62
MAPT P10636 5/20 0.62
KMT2A Q03164 4/20 0.62
TP53 P04637 3/20 0.62
CYP3A4 P08684 3/20 0.62
ALOX15 P16050 3/20 0.62
MAPK1 P28482 3/20 0.62
MEN1 O00255 3/20 0.62
RECQL P46063 3/20 0.62
ST6GAL1 P15907 2/20 0.62
CYP2C9 P11712 2/20 0.62
ALOX12 P18054 2/20 0.62
CDK2 P24941 2/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
TERT O14746 1/20 0.55
POLH Q9Y253 6/20 0.52
GAA P10253 2/20 0.50
PTPN1 P18031 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119937 0.89 MEN1 (0.61) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL13056276 0.87 KDM4E (0.55) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL13056270 0.86 KDM4E (0.56) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL4165699 0.84 POLH (0.71) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL2396323 0.84 HSD17B10 (0.66) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL3757805 0.84 POLH (0.74) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL3757815 0.82 KDM4E (0.62) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL2397536 0.81 KDM4E (0.64) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL3723524 0.81 TP53 (0.53) KDM4EHSD17B10MAPTKMT2ATP53
SCHEMBL3282447 0.80 KDM4E (0.71) KDM4EHSD17B10MAPTKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
WO-2010129138-A2 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT PC, PCK1, PYGL KDM4E 3745/4885HSD17B10 232/4885MAPT 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.